Want to see ABCL full AI Analyst Report?
Revenue by Segment
Breaks down earnings across different business areas, revealing which segments are driving growth and where there may be vulnerabilities.AbCellera's revenue streams have seen significant shifts, with royalties dropping to zero since early 2023, impacting overall revenue. Licensing and research fees show inconsistent growth, while milestone payments remain sporadic. The earnings call highlights a strategic pivot towards internal development, particularly ABCL635, despite revenue declines and increased net losses. This shift aims to capitalize on a $2 billion market opportunity, supported by strong liquidity. However, paused development programs may hinder short-term revenue recovery, emphasizing the company's reliance on future clinical successes.
Date | Licensing | Royalty | Research Fees | Milestone Payments |
|---|---|---|---|---|
Jun 30, 2026 | $149.00K | $0.00 | $3.90M | $0.00 |
Mar 31, 2026 | $191.00K | $0.00 | $8.12M | $0.00 |
Dec 31, 2025 | $36.17M | $0.00 | $7.68M | $1.00M |
Sep 30, 2025 | $138.00K | $0.00 | $8.82M | $0.00 |
Jun 30, 2025 | $10.45M | $0.00 | $6.64M | $0.00 |
Mar 31, 2025 | $167.00K | $0.00 | $4.07M | $0.00 |
Dec 31, 2024 | $281.00K | $0.00 | $4.77M | $0.00 |
Sep 30, 2024 | $218.00K | $0.00 | $6.29M | $0.00 |
Jun 30, 2024 | $370.00K | $0.00 | $5.45M | $1.50M |
Mar 31, 2024 | $180.00K | $0.00 | $9.77M | $0.00 |